CA2885566C - Compositions and methods for increasing human growth hormone levels - Google Patents
Compositions and methods for increasing human growth hormone levels Download PDFInfo
- Publication number
- CA2885566C CA2885566C CA2885566A CA2885566A CA2885566C CA 2885566 C CA2885566 C CA 2885566C CA 2885566 A CA2885566 A CA 2885566A CA 2885566 A CA2885566 A CA 2885566A CA 2885566 C CA2885566 C CA 2885566C
- Authority
- CA
- Canada
- Prior art keywords
- nutritional supplement
- mmol
- human
- use according
- supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title description 55
- 108010000521 Human Growth Hormone Proteins 0.000 title description 55
- 239000000854 Human Growth Hormone Substances 0.000 title description 54
- 230000001965 increasing effect Effects 0.000 title description 22
- 239000000203 mixture Substances 0.000 title description 22
- 238000000034 method Methods 0.000 title description 14
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 67
- 241000282414 Homo sapiens Species 0.000 claims abstract description 25
- 239000004472 Lysine Substances 0.000 claims abstract description 21
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 20
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims abstract description 19
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 16
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 15
- 230000004060 metabolic process Effects 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 11
- 241000951473 Schizonepeta Species 0.000 claims abstract description 10
- 235000019766 L-Lysine Nutrition 0.000 claims abstract description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 9
- 229930064664 L-arginine Natural products 0.000 claims abstract description 9
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 9
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 4
- 239000013589 supplement Substances 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- 229960003646 lysine Drugs 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- 239000004475 Arginine Substances 0.000 description 11
- 229960003121 arginine Drugs 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 102000018997 Growth Hormone Human genes 0.000 description 6
- 108010051696 Growth Hormone Proteins 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 239000000122 growth hormone Substances 0.000 description 6
- 230000000580 secretagogue effect Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000009699 differential effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 2
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 235000005550 amino acid supplement Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A nutritional supplement and a use thereof orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: L-arginine; Oxo-proline;
L-lysine; N-acetyl L-cysteine; L-glutamine; and Schizonepeta aerial parts powder.
L-lysine; N-acetyl L-cysteine; L-glutamine; and Schizonepeta aerial parts powder.
Description
COMPOSITIONS AND METHODS FOR INCREASING HUMAN GROWTH
HORMONE LEVELS
PRIORITY CLAIM
This application claims the benefit of the filing date of: United States Patent Application Serial Number 13/623,114, filed September 20, 2012, for "METHODS
FOR INCREASING HUMAN GROWTH HORMONE LEVELS"; United States Patent Application Serial Number 13/623,117, filed September 20, 2012, for "COMPOSITIONS FOR INCREASING HUMAN GROWTH HORMONE
LEVELS"; United States Patent Application Serial Number 13/623,118, filed September 20, 2012, for "METHODS FOR INCREASING ENDURANCE AND
FAT METABOLISM IN HUMANS"; and United States Patent Application Serial Number 13/623,112, filed September 20, 2012, for "COMPOSITIONS AND
METHODS FOR INCREASING HUMAN GROWTH HORMONE LEVELS."
TECHNICAL FIELD
Embodiments of the invention generally relate to compositions and methods for increasing human growth hormone (hGH) levels in healthy human beings and for increasing endurance and fat metabolism in humans.
BACKGROUND
The primary biological function of hGH includes stimulating growth, cell repair and regeneration. Once the growth period of adolescence concludes, the primary function of hGH in adulthood becomes that of cell regeneration and repair, helping to regenerate skin, bones, heart, lungs, liver and kidneys to their optimal, youthful cell levels. As is the case with many of our other hormones or their pre-cursors, such as testosterone, estrogen, progesterone, DHEA and melatonin, hGH levels decline with age. Therapeutically, many of these hormones can be replaced to offset some of the effects of aging such as menopausal symptoms in women or erectile dysfunction in men. The human body, like every other living entity, works on daily, or circadian, as well as monthly and annual rhythms. Daily growth hormone secretion diminishes with age with roughly half the levels at age forty that we had when we were twenty, and
HORMONE LEVELS
PRIORITY CLAIM
This application claims the benefit of the filing date of: United States Patent Application Serial Number 13/623,114, filed September 20, 2012, for "METHODS
FOR INCREASING HUMAN GROWTH HORMONE LEVELS"; United States Patent Application Serial Number 13/623,117, filed September 20, 2012, for "COMPOSITIONS FOR INCREASING HUMAN GROWTH HORMONE
LEVELS"; United States Patent Application Serial Number 13/623,118, filed September 20, 2012, for "METHODS FOR INCREASING ENDURANCE AND
FAT METABOLISM IN HUMANS"; and United States Patent Application Serial Number 13/623,112, filed September 20, 2012, for "COMPOSITIONS AND
METHODS FOR INCREASING HUMAN GROWTH HORMONE LEVELS."
TECHNICAL FIELD
Embodiments of the invention generally relate to compositions and methods for increasing human growth hormone (hGH) levels in healthy human beings and for increasing endurance and fat metabolism in humans.
BACKGROUND
The primary biological function of hGH includes stimulating growth, cell repair and regeneration. Once the growth period of adolescence concludes, the primary function of hGH in adulthood becomes that of cell regeneration and repair, helping to regenerate skin, bones, heart, lungs, liver and kidneys to their optimal, youthful cell levels. As is the case with many of our other hormones or their pre-cursors, such as testosterone, estrogen, progesterone, DHEA and melatonin, hGH levels decline with age. Therapeutically, many of these hormones can be replaced to offset some of the effects of aging such as menopausal symptoms in women or erectile dysfunction in men. The human body, like every other living entity, works on daily, or circadian, as well as monthly and annual rhythms. Daily growth hormone secretion diminishes with age with roughly half the levels at age forty that we had when we were twenty, and
-2-about one-third of those youthful levels at age sixty. In some sixty-year olds, the levels are as low as 25% of the hGH levels in a twenty-year old. Symptoms of aging include loss of muscle, increase of fat, decreased physical mobility, decreased energy levels and as a result, diminished socialization, diminished healing ability and an increased risk of cardiovascular disease and decreased life expectancy. Low hGH levels are associated with the aging process and early onset of disease. For example, Rosen and Bengtsson noted an increased death rate from cardiovascular disease in hGH
deficient patients (Rosen, T., Bengtsson, B. A., Lancet 336 (1990): 285-2880).
Until recently human growth hormone (hereinafter alternatively referred to as hGH) was available only in expensive injectable forms, and benefits from the restoration of hGH levels available only to those with the ability to pay.
Most recently natural substances that can trigger the release of human growth hormone from an individual's own anterior pituitary gland have become available. These are generically referred to as secretagogues. Secretagogues have the ability to restore hGH
levels, potentially to the levels found in youth. See for reference the book entitled "Grow Young With hGH" by Dr. Ronald Klatz, President of the American Academy of Anti-Aging, published in 1997 by Harper Collins.
HGH-deficient adults have marked reductions in lean body mass, and within months of hGH treatment, gains in lean body mass, skin thickness and muscle mass are observed. (Cuneo RC et al. J Appl Physiol 1991;70:695-700; Cuneo RC et al. J
Appl Physiol 1991;70:688-694; Rudman D et al. N Engl J Med 1969;280:1434-1438).
It is well-established that intravenous (IV) administration of some amino acids results in significant hGH secretion. Intravenous infusion of 183mg of argininelg body weight in females increased hGH levels >20-fold and 30g of arginine elevated serum hGH levels 8.6 fold in males. (Merimee TJ et al. N Engl J Med 1969;280:1434-1438; Alba-Roth J et al. J Clin Endocrinol Metab 1988;67:1186-1189).
Other amino acids, such as methionine, phenylalanine, lysine, histidine, and omithine have also led to marked increases in hGH (Alba-Roth, Muller, Schopohl, & von Werder, 1988; Chromiak & Antonio, 2002; Gourmelen, M., M. Donnadieu, et al.
(1972) Ann Endocrinol (Paris) 33(5): 526-528).
Given the difficulties in IV administration of amino acids for widespread use, interest in elucidating the hGH response to oral amino acid supplements prompted
deficient patients (Rosen, T., Bengtsson, B. A., Lancet 336 (1990): 285-2880).
Until recently human growth hormone (hereinafter alternatively referred to as hGH) was available only in expensive injectable forms, and benefits from the restoration of hGH levels available only to those with the ability to pay.
Most recently natural substances that can trigger the release of human growth hormone from an individual's own anterior pituitary gland have become available. These are generically referred to as secretagogues. Secretagogues have the ability to restore hGH
levels, potentially to the levels found in youth. See for reference the book entitled "Grow Young With hGH" by Dr. Ronald Klatz, President of the American Academy of Anti-Aging, published in 1997 by Harper Collins.
HGH-deficient adults have marked reductions in lean body mass, and within months of hGH treatment, gains in lean body mass, skin thickness and muscle mass are observed. (Cuneo RC et al. J Appl Physiol 1991;70:695-700; Cuneo RC et al. J
Appl Physiol 1991;70:688-694; Rudman D et al. N Engl J Med 1969;280:1434-1438).
It is well-established that intravenous (IV) administration of some amino acids results in significant hGH secretion. Intravenous infusion of 183mg of argininelg body weight in females increased hGH levels >20-fold and 30g of arginine elevated serum hGH levels 8.6 fold in males. (Merimee TJ et al. N Engl J Med 1969;280:1434-1438; Alba-Roth J et al. J Clin Endocrinol Metab 1988;67:1186-1189).
Other amino acids, such as methionine, phenylalanine, lysine, histidine, and omithine have also led to marked increases in hGH (Alba-Roth, Muller, Schopohl, & von Werder, 1988; Chromiak & Antonio, 2002; Gourmelen, M., M. Donnadieu, et al.
(1972) Ann Endocrinol (Paris) 33(5): 526-528).
Given the difficulties in IV administration of amino acids for widespread use, interest in elucidating the hGH response to oral amino acid supplements prompted
-3-testing of such supplements containing mainly arginine, lysine and ornithine at varying amounts. Yet the pronounced variability in results among these studies, which differed in aspects including subject population, supplement composition, and dosage methodologies, make clear the complexities involved in the design of an effective supplement for supporting hGH levels in the general public. (Surninski RR et al. Int J
Sport Nutr 1997;7:48-60; Lambert MI et al. Int J Sport Nutr 1993;3:298-305;
Corpas E
et al. J Gerontol 1993;48:M128-M133; Isidori A et al. Curr Med Res Opin 1981;7:475-481; Fogelholm GM et al. Int J Sport Nutr 1993;3:290-297; Chromiak JA, Antonio J. Nutrition 2002 Jul;18(7-8):657-61).
Thus, determination of an effective and safe oral functional blend that stimulates hGH secretion in the general population is important to determine since athletes, entertainers and now the general public seek effective hGH support supplements and understand hGH to have rejuvenating properties.
Indeed, once partial to athletes and entertainers, the desire for effective supplements to provoke growth hormone (hGH) increases now extends to the general public. Not only do they have a goal of building lean tissue and reducing fat, but also in improving skin quality and other rejuvenating qualities that hGH is understood to provide. Despite proceeding literature on oral amino acids for use in stimulating hGH, evidence for an optimized oral amino acid-containing blend able to stimulate hGH in the general public including both men and women of a wide age range is not clear.
It would be desirable to provide a nutritional supplement for elevating hGH
release, in particular an amino acid-containing composition that is well tolerated having the result of increasing or elevating hGH release in those individuals whose hGH
release rates have slowed as a function of increasing age or that have normal hGH
levels but desire higher hGH levels. Although some existing nutritional supplements claim to impact the production of natural human growth hormone, there is a need for an improved nutritional supplement that efficiently enhances the production and effect of natural human growth hormone in the general population.
DISCLOSURE
3a In some embodiments, there is provided a use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 0.1 to 6 mmol L-arginine; 0.1 to 8 mmol Oxo-proline; 0.1 to 12 mmol L-lysine; 0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
In some embodiments, there is provided a use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising 3.44 mmol L-arginine; 5.30 mmol Oxo-proline; 8.21 mmol L-lysine; 6.13 pmol N-acetyl L-cysteine; and 6.84 [tmol L-glutamine.
In some embodiments, there is provided a nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 0.1 to 6 mmol L-arginine; 0.1 to 8 mmol Oxo-proline; 0.1 to 12 mmol L-lysine; 0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
In some embodiments, there is provided a nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 3.44 mmol L-arginine; 5.30 mmol Oxo-proline; 8.21 mmol L-lysine; 6.13 pmol N-acetyl L cysteine; and 6.84 [tmol L-glutamine.
The nutritional supplements described herein may also include schizonepeta.
Date Recue/Date Received 2020-11-10
Sport Nutr 1997;7:48-60; Lambert MI et al. Int J Sport Nutr 1993;3:298-305;
Corpas E
et al. J Gerontol 1993;48:M128-M133; Isidori A et al. Curr Med Res Opin 1981;7:475-481; Fogelholm GM et al. Int J Sport Nutr 1993;3:290-297; Chromiak JA, Antonio J. Nutrition 2002 Jul;18(7-8):657-61).
Thus, determination of an effective and safe oral functional blend that stimulates hGH secretion in the general population is important to determine since athletes, entertainers and now the general public seek effective hGH support supplements and understand hGH to have rejuvenating properties.
Indeed, once partial to athletes and entertainers, the desire for effective supplements to provoke growth hormone (hGH) increases now extends to the general public. Not only do they have a goal of building lean tissue and reducing fat, but also in improving skin quality and other rejuvenating qualities that hGH is understood to provide. Despite proceeding literature on oral amino acids for use in stimulating hGH, evidence for an optimized oral amino acid-containing blend able to stimulate hGH in the general public including both men and women of a wide age range is not clear.
It would be desirable to provide a nutritional supplement for elevating hGH
release, in particular an amino acid-containing composition that is well tolerated having the result of increasing or elevating hGH release in those individuals whose hGH
release rates have slowed as a function of increasing age or that have normal hGH
levels but desire higher hGH levels. Although some existing nutritional supplements claim to impact the production of natural human growth hormone, there is a need for an improved nutritional supplement that efficiently enhances the production and effect of natural human growth hormone in the general population.
DISCLOSURE
3a In some embodiments, there is provided a use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 0.1 to 6 mmol L-arginine; 0.1 to 8 mmol Oxo-proline; 0.1 to 12 mmol L-lysine; 0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
In some embodiments, there is provided a use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising 3.44 mmol L-arginine; 5.30 mmol Oxo-proline; 8.21 mmol L-lysine; 6.13 pmol N-acetyl L-cysteine; and 6.84 [tmol L-glutamine.
In some embodiments, there is provided a nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 0.1 to 6 mmol L-arginine; 0.1 to 8 mmol Oxo-proline; 0.1 to 12 mmol L-lysine; 0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
In some embodiments, there is provided a nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 3.44 mmol L-arginine; 5.30 mmol Oxo-proline; 8.21 mmol L-lysine; 6.13 pmol N-acetyl L cysteine; and 6.84 [tmol L-glutamine.
The nutritional supplements described herein may also include schizonepeta.
Date Recue/Date Received 2020-11-10
-4-The present invention relates to a nutritional supplement and method of using the same. It is an amino acid-containing secretagogue composition, which, taken orally, stimulates the pituitary gland to increase serum levels of hGH.
Also described herein are nutritional supplement and method of using the same.
The nutritional supplement includes an amino acid secretagogue composition, which, taken orally, stimulates the pituitary gland to release hGH.
A particular embodiment of the present disclosure relates to an oral nutritional supplement that includes the amino acids 1-lysine, 1-arginine, oxo-proline, and one of either cysteine or glutamine. The amino acids may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, and mixtures thereof which are effective to increase hGH levels in the general population.
Another particular embodiment relates to an oral nutritional supplement that consists essentially of 1-lysine HC1, 1-arginine HC1, oxo-prolinc, N-acety1-1-cysteine, 1-glutamine, and sehizonepeta (aerial parts) powder.
Other embodiments are drawn to methods of increasing human growth hormone in humans that include orally administering the disclosed nutritional supplement to a healthy human being. Alternative embodiments are drawn to methods of administering the disclosed nutritional supplements to a human being to improve endurance and fat metabolism.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows growth hormone levels after supplement administration compared to a placebo.
MODE(S) FOR CARRYING OUT THE INVENTION
The present invention relates to a method of use of a nutritional supplement by a human being. The nutritional supplement is an amino acid-containing secretagogue composition, which, taken orally, stimulates the pituitary gland to produce hGH.
Increased production of hGH may result in inhibition of insulin depression, inhibition of hyperglycemia and increase in insulin effectiveness, enhancement of fat conversion,
Also described herein are nutritional supplement and method of using the same.
The nutritional supplement includes an amino acid secretagogue composition, which, taken orally, stimulates the pituitary gland to release hGH.
A particular embodiment of the present disclosure relates to an oral nutritional supplement that includes the amino acids 1-lysine, 1-arginine, oxo-proline, and one of either cysteine or glutamine. The amino acids may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, and mixtures thereof which are effective to increase hGH levels in the general population.
Another particular embodiment relates to an oral nutritional supplement that consists essentially of 1-lysine HC1, 1-arginine HC1, oxo-prolinc, N-acety1-1-cysteine, 1-glutamine, and sehizonepeta (aerial parts) powder.
Other embodiments are drawn to methods of increasing human growth hormone in humans that include orally administering the disclosed nutritional supplement to a healthy human being. Alternative embodiments are drawn to methods of administering the disclosed nutritional supplements to a human being to improve endurance and fat metabolism.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows growth hormone levels after supplement administration compared to a placebo.
MODE(S) FOR CARRYING OUT THE INVENTION
The present invention relates to a method of use of a nutritional supplement by a human being. The nutritional supplement is an amino acid-containing secretagogue composition, which, taken orally, stimulates the pituitary gland to produce hGH.
Increased production of hGH may result in inhibition of insulin depression, inhibition of hyperglycemia and increase in insulin effectiveness, enhancement of fat conversion,
-5-lowering of cholesterol, and normalization of lipid balance. The supplement of the present invention works as a dietary supplement by assisting the body's own ability to secrete hGH naturally in a manner which is safe and effective, as well as being affordable.
A particular embodiment of the present disclosure relates to an oral nutritional supplement that includes 1-lysine, 1-arginine, oxo-proline, and one of either cysteine or glutamine. The supplement may additionally include both cysteine and glutamine and/or schizonepeta powder. In particular embodiments, a functional dosage includes the 1-arginine at a level between 0.1-6 mmol and the oxo-proline between 0.1-8 mmol, and/or the 1-lysine in an amount between 0.1-12 mmol. The cysteine and/or glutamine may be contained at a level between 0.001-6 mmol. In another particular embodiment, a functional dosage includes the 1-arginine at a level between 2.5-4.5 mmol and the oxo-proline between 4-6 mmol, and/or the 1-lysine in an amount between 7-9 mmol.
The cysteine and/or glutamine may be contained at a level between 0.001-0.5 mmol.
The cysteine can be n-acetyl L-cysteine and the glutamine may be 1-glutamine.
The amino acids may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, and mixtures thereof which are effective to increase hGH levels in the general population.
The nutritional supplement may be present in an amount of 2.9 grams. The nutritional supplement may be in any acceptable and known oral formulation, such as powder, tablet, capsule, liquid, or wafer form.
Another particular embodiment relates to an oral nutritional supplement that consists essentially of 1-lysine HC1, 1-arginine HC1, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizoncpeta (aerial parts) powder. In particular embodiments, a functional dosage includes the 1-arginine HC1 at a level between 0.1-6 mmol and the oxo-proline between 0.1-8 mmol, and/or the 1-lysine HC1 in an amount between 0.1-12 mmol. The n-acetyl L-cysteine and/or 1-glutamine may be contained at a level between 0.001-6 mmol. In another particular embodiment, a functional dosage includes the 1-arginine HC1 at a level between 2.5-4.5 mmol and the oxo-proline between 4-6 mmol, and/or the 1-lysine HCl in an amount between 7-9 mmol. The n-acetyl L-cysteine and/or 1-glutamine may be contained at a level between 0.001-0.5 mmol.
A particular embodiment of the present disclosure relates to an oral nutritional supplement that includes 1-lysine, 1-arginine, oxo-proline, and one of either cysteine or glutamine. The supplement may additionally include both cysteine and glutamine and/or schizonepeta powder. In particular embodiments, a functional dosage includes the 1-arginine at a level between 0.1-6 mmol and the oxo-proline between 0.1-8 mmol, and/or the 1-lysine in an amount between 0.1-12 mmol. The cysteine and/or glutamine may be contained at a level between 0.001-6 mmol. In another particular embodiment, a functional dosage includes the 1-arginine at a level between 2.5-4.5 mmol and the oxo-proline between 4-6 mmol, and/or the 1-lysine in an amount between 7-9 mmol.
The cysteine and/or glutamine may be contained at a level between 0.001-0.5 mmol.
The cysteine can be n-acetyl L-cysteine and the glutamine may be 1-glutamine.
The amino acids may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, and mixtures thereof which are effective to increase hGH levels in the general population.
The nutritional supplement may be present in an amount of 2.9 grams. The nutritional supplement may be in any acceptable and known oral formulation, such as powder, tablet, capsule, liquid, or wafer form.
Another particular embodiment relates to an oral nutritional supplement that consists essentially of 1-lysine HC1, 1-arginine HC1, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizoncpeta (aerial parts) powder. In particular embodiments, a functional dosage includes the 1-arginine HC1 at a level between 0.1-6 mmol and the oxo-proline between 0.1-8 mmol, and/or the 1-lysine HC1 in an amount between 0.1-12 mmol. The n-acetyl L-cysteine and/or 1-glutamine may be contained at a level between 0.001-6 mmol. In another particular embodiment, a functional dosage includes the 1-arginine HC1 at a level between 2.5-4.5 mmol and the oxo-proline between 4-6 mmol, and/or the 1-lysine HCl in an amount between 7-9 mmol. The n-acetyl L-cysteine and/or 1-glutamine may be contained at a level between 0.001-0.5 mmol.
-6-The nutritional supplement may be in any acceptable and known oral formulation, such as powder, tablet, capsule, liquid, or wafer form.
Other embodiments are drawn to methods of increasing human growth hormone in humans that include orally administering the disclosed nutritional supplement to a healthy human being. As used herein, "healthy human being"
means a human being without any physiological deficiency in hGH independent of age.
Particular embodiments of the invention relate to oral administration of the disclosed nutritional supplement to a human that is at least 30 years old. The nutritional supplement may be administered from one to three times daily or, alternatively, may be administered every other day, or may be administered once a week. In particular embodiments, the nutritional supplement may be administered on an empty stomach.
The disclosed nutritional supplements can be orally administering to a human being to improve health, including by improving endurance and increasing fat metabolism. The disclosed nutritional supplements can also be used in combination with testosterone or testosterone-boosting supplements to enhance the effect of the nutritional supplements disclosed herein.
In accordance with the "consist essentially of" and "consisting essentially of"
language, the nutritional supplement of the third embodiments is essentially limited to the aforementioned ingredients and does not include any additional active ingredients intended to add nutritional content (e.g., vitamins, minerals, etc.), but may include additional ingredients not intended to add nutritional content such as ingredients intended to fulfill a non-nutritional purpose (e.g., coloring, fillers, flavoring, an ingredient for maintaining the structural form, etc.).
Each ingredient of the nutritional supplement of the present invention may be prepared in accordance with any method known to one of ordinary skill in the art.
Alternatively, each ingredient may be obtained in a fully prepared from a commercially available source.
The nutritional supplement of the present invention may be in any suitable oral administration form, including but not limited to: a chewable form, a liquid form, a spray form, a capsule form, a suppository form, dissolvable wafer, and a powder form.
Other embodiments are drawn to methods of increasing human growth hormone in humans that include orally administering the disclosed nutritional supplement to a healthy human being. As used herein, "healthy human being"
means a human being without any physiological deficiency in hGH independent of age.
Particular embodiments of the invention relate to oral administration of the disclosed nutritional supplement to a human that is at least 30 years old. The nutritional supplement may be administered from one to three times daily or, alternatively, may be administered every other day, or may be administered once a week. In particular embodiments, the nutritional supplement may be administered on an empty stomach.
The disclosed nutritional supplements can be orally administering to a human being to improve health, including by improving endurance and increasing fat metabolism. The disclosed nutritional supplements can also be used in combination with testosterone or testosterone-boosting supplements to enhance the effect of the nutritional supplements disclosed herein.
In accordance with the "consist essentially of" and "consisting essentially of"
language, the nutritional supplement of the third embodiments is essentially limited to the aforementioned ingredients and does not include any additional active ingredients intended to add nutritional content (e.g., vitamins, minerals, etc.), but may include additional ingredients not intended to add nutritional content such as ingredients intended to fulfill a non-nutritional purpose (e.g., coloring, fillers, flavoring, an ingredient for maintaining the structural form, etc.).
Each ingredient of the nutritional supplement of the present invention may be prepared in accordance with any method known to one of ordinary skill in the art.
Alternatively, each ingredient may be obtained in a fully prepared from a commercially available source.
The nutritional supplement of the present invention may be in any suitable oral administration form, including but not limited to: a chewable form, a liquid form, a spray form, a capsule form, a suppository form, dissolvable wafer, and a powder form.
-7-Irrespective of the structural form of the nutritional supplement, the ingredients of the nutritional supplement may be distributed homogeneously or non-homogeneously within the nutritional supplement.
The nutritional supplement of the present invention may be ingested on a regular basis, such as a daily or weekly intake at a dosage tailored to an individual's needs; i.e., the nutritional supplement is to be taken regularly as multiples (lx, 2x, etc.) of the structural units (pills, tablets, capsules, liquid dose, etc.) in accordance with the needs of the individual. For example, a senior citizen leading a sedentary life may need higher daily doses than does a young person engaged in regular strenuous exercise (e.g., a weight lifter). Alternatively, the nutritional supplement of the present invention may be ingested on an as-needed basis at a dosage tailored to the individual's needs.
Medical or nutritional counseling may be beneficial for arriving at a desirable or optimal dosage tailored to the individual's needs.
The combination of types of amino acids, mass ranges, and specific formulations have been selected to be synergistically balanced and of adequate quantity to achieve the desired physiological effect, namely, growth hormone release.
Improper combinations of the amino acids may be ineffective. The component amino acids are synergistic in the sense that several of them when combined together, synergistically stimulate the release of human growth hormone. The combination was also chosen to reduce or inhibit chemical combination or reaction between the amino acids.
EXAMPLES
Example 1 A cross-over, placebo controlled, double-blind study involved 16 healthy subjects [12 males, 4 females; 9 Caucasian, 6 African American, 1 other; mean age= 32 14 years; body mass index=26.4 5.0 ranging from 19.1 to 36.8kg/m2].
Each subject reported to the Inpatient Unit on two occasions one week apart. After an overnight fast, subjects had an IV line placed and baseline bloods samples were drawn at -30, -15, and 0 minutes. Subjects were then asked to swallow the capsules of the test supplement or an identical looking placebo.
The nutritional supplement of the present invention may be ingested on a regular basis, such as a daily or weekly intake at a dosage tailored to an individual's needs; i.e., the nutritional supplement is to be taken regularly as multiples (lx, 2x, etc.) of the structural units (pills, tablets, capsules, liquid dose, etc.) in accordance with the needs of the individual. For example, a senior citizen leading a sedentary life may need higher daily doses than does a young person engaged in regular strenuous exercise (e.g., a weight lifter). Alternatively, the nutritional supplement of the present invention may be ingested on an as-needed basis at a dosage tailored to the individual's needs.
Medical or nutritional counseling may be beneficial for arriving at a desirable or optimal dosage tailored to the individual's needs.
The combination of types of amino acids, mass ranges, and specific formulations have been selected to be synergistically balanced and of adequate quantity to achieve the desired physiological effect, namely, growth hormone release.
Improper combinations of the amino acids may be ineffective. The component amino acids are synergistic in the sense that several of them when combined together, synergistically stimulate the release of human growth hormone. The combination was also chosen to reduce or inhibit chemical combination or reaction between the amino acids.
EXAMPLES
Example 1 A cross-over, placebo controlled, double-blind study involved 16 healthy subjects [12 males, 4 females; 9 Caucasian, 6 African American, 1 other; mean age= 32 14 years; body mass index=26.4 5.0 ranging from 19.1 to 36.8kg/m2].
Each subject reported to the Inpatient Unit on two occasions one week apart. After an overnight fast, subjects had an IV line placed and baseline bloods samples were drawn at -30, -15, and 0 minutes. Subjects were then asked to swallow the capsules of the test supplement or an identical looking placebo.
-8-The administered supplement is a novel 2.9g/dose blend of 1-lysine HC1, 1-arginine HC1, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder.
Blood was drawn at 15, 30, 60 and 90 and 120 minutes for assay. Human GH
was measured at each time point using the Siemens Immulite 2000 (infra-assay CV
was 3.72%, inter-assay CV was 5.70%, and the detection limit for GH was 0.05ng/ml.
Mean growth hormone increased eight-fold over baseline (equivalent to 682%) after the supplement from 0.17 at baseline to 1.33ng/m1 at 120 minutes compared to a mean decrease of 52% after placebo from 0.93 to 0.45ng/m1 (FIG. 1). The mean change in GH levels from baseline to 120 minutes (GH at 120 minutes minus GH
at 0 minutes), was 1.15 (95% CI: 0.17, 2.14) ng/ml after the supplement versus -0.48 (-1.47, 0.50) ng/ml after the placebo, demonstrating a statistically significant differential effect (P=0.01). After the supplement, the mean AUC for GH across 120 minutes was 20.43 (95% CI: 19.90, 20.95) ng/ml/min which was significantly higher (P=0.04) than placebo at 19.67 (18.74, 20.59) ng/ml/min. Overall, 120 minutes after taking the supplement, GH levels were significantly higher in both absolute levels and by AUC.
Mean levels of GH reached after the subcutaneous injection of 0.06 IU of HGH
in the treatment of GH deficient subjects was 0.4ng/ml, a value that was clearly in the range of values seen in our study with oral amino acids (Janssen YJ et al. Br J Clin Pharmacol 1999;47:273-278).
The present study is distinct in that it had a broad range of ages and BMI's and included both genders. An additional advantage of this study of the amino-acid containing blend over previous hGH evaluations is that it contained a placebo control group and was randomized and double-blinded.
Example 2 The short-term effects of a single oral nutritional supplement on hGH levels 2 hours post ingestion was studied 16 healthy subjects [12 males, 4 females;
Blood was drawn at 15, 30, 60 and 90 and 120 minutes for assay. Human GH
was measured at each time point using the Siemens Immulite 2000 (infra-assay CV
was 3.72%, inter-assay CV was 5.70%, and the detection limit for GH was 0.05ng/ml.
Mean growth hormone increased eight-fold over baseline (equivalent to 682%) after the supplement from 0.17 at baseline to 1.33ng/m1 at 120 minutes compared to a mean decrease of 52% after placebo from 0.93 to 0.45ng/m1 (FIG. 1). The mean change in GH levels from baseline to 120 minutes (GH at 120 minutes minus GH
at 0 minutes), was 1.15 (95% CI: 0.17, 2.14) ng/ml after the supplement versus -0.48 (-1.47, 0.50) ng/ml after the placebo, demonstrating a statistically significant differential effect (P=0.01). After the supplement, the mean AUC for GH across 120 minutes was 20.43 (95% CI: 19.90, 20.95) ng/ml/min which was significantly higher (P=0.04) than placebo at 19.67 (18.74, 20.59) ng/ml/min. Overall, 120 minutes after taking the supplement, GH levels were significantly higher in both absolute levels and by AUC.
Mean levels of GH reached after the subcutaneous injection of 0.06 IU of HGH
in the treatment of GH deficient subjects was 0.4ng/ml, a value that was clearly in the range of values seen in our study with oral amino acids (Janssen YJ et al. Br J Clin Pharmacol 1999;47:273-278).
The present study is distinct in that it had a broad range of ages and BMI's and included both genders. An additional advantage of this study of the amino-acid containing blend over previous hGH evaluations is that it contained a placebo control group and was randomized and double-blinded.
Example 2 The short-term effects of a single oral nutritional supplement on hGH levels 2 hours post ingestion was studied 16 healthy subjects [12 males, 4 females;
9 Caucasian, 6 African American, 1 other; mean age= 32 14 years; body mass index=26.4 5.0 ranging from 19.1 to 36.8kg/m21. Each subject reported to the Inpatient Unit on two occasions one week apart. After an overnight fast, subjects had an W line placed and baseline bloods samples were drawn at -30, -15, and 0 minutes.
Subjects were then asked to swallow the capsules of supplement (SER0VITAL ) or an identical looking placebo. SEROVITAL is a 2.9g/dose blend of 1-lysine HC1, 1-arginine HCL, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder. Blood was drawn at 15, 30, 60 and 90 and 120 minutes for assay. Human GH was measured at each time point using the Siemens Immulite 2000 (intra-assay CV was 3.72%, inter-assay CV was 5.70%, and the detection limit for GH was 0.05ng/ml. The -15 and 120 minute time points were additionally assayed for triiodothyronine (T3) as informative for mechanistic investigations.
The mean growth hormone increased 682% after the supplement from 0.17 at baseline to 1.33ng/m1 at 120 minutes compared to a mean decrease of 52% after the placebo from 0.93 to 0.45ng/m1 (FIG. 1).
The mean change in GH levels from baseline to 120 minutes (GH at 120 minutes minus GH at 0 minutes), was 1.15 (95% CI: 0.17, 2.14) ng/m1 after the supplement versus -0.48 (-1.47, 0.50) ng/ml after the placebo, demonstrating a statistically significant differential effect (P=0.01). After the supplement, the mean AUC for GH across 120 minutes was 20.43 (95% CI: 19.90, 20.95) ng/ml/min, which was significantly higher (P=0.04) than placebo at 19.67 (18.74, 20.59) ng/ml/min.
Overall, 120 minutes after taking the supplement, GH levels were significantly higher in absolute levels or by AUC.
As daily circadian levels of T3 naturally decrease during the morning hours, at which the current trial was scheduled, it was not surprising that placebo levels between the -15 and 120 minute time points decreased by -6.10 ng/dL (106 to 100 ng/dL, P=0.01). In contrast, the SERoViTALER) group exhibited a deceased reduction inT3 by nearly one-half over the same time course, -3.3 ng/dL (101-97.3 ng/dL, NS), which was not a significant reduction compared to baseline, as was the reduction in the placebo group. These results affirm that somatostatin inhibition plays a mechanistic role in the ability of SER0VITALO to induce significant increases in serum GH
levels in human subjects.
Subjects were then asked to swallow the capsules of supplement (SER0VITAL ) or an identical looking placebo. SEROVITAL is a 2.9g/dose blend of 1-lysine HC1, 1-arginine HCL, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder. Blood was drawn at 15, 30, 60 and 90 and 120 minutes for assay. Human GH was measured at each time point using the Siemens Immulite 2000 (intra-assay CV was 3.72%, inter-assay CV was 5.70%, and the detection limit for GH was 0.05ng/ml. The -15 and 120 minute time points were additionally assayed for triiodothyronine (T3) as informative for mechanistic investigations.
The mean growth hormone increased 682% after the supplement from 0.17 at baseline to 1.33ng/m1 at 120 minutes compared to a mean decrease of 52% after the placebo from 0.93 to 0.45ng/m1 (FIG. 1).
The mean change in GH levels from baseline to 120 minutes (GH at 120 minutes minus GH at 0 minutes), was 1.15 (95% CI: 0.17, 2.14) ng/m1 after the supplement versus -0.48 (-1.47, 0.50) ng/ml after the placebo, demonstrating a statistically significant differential effect (P=0.01). After the supplement, the mean AUC for GH across 120 minutes was 20.43 (95% CI: 19.90, 20.95) ng/ml/min, which was significantly higher (P=0.04) than placebo at 19.67 (18.74, 20.59) ng/ml/min.
Overall, 120 minutes after taking the supplement, GH levels were significantly higher in absolute levels or by AUC.
As daily circadian levels of T3 naturally decrease during the morning hours, at which the current trial was scheduled, it was not surprising that placebo levels between the -15 and 120 minute time points decreased by -6.10 ng/dL (106 to 100 ng/dL, P=0.01). In contrast, the SERoViTALER) group exhibited a deceased reduction inT3 by nearly one-half over the same time course, -3.3 ng/dL (101-97.3 ng/dL, NS), which was not a significant reduction compared to baseline, as was the reduction in the placebo group. These results affirm that somatostatin inhibition plays a mechanistic role in the ability of SER0VITALO to induce significant increases in serum GH
levels in human subjects.
-10-At 120 minutes, GH concentrations were 2-fold higher in women (2.3 1.1ng/ml, n=4) than in men (1.0 0.4 ng/ml, n= 12, although the study was not adequately powered for these comparisons. Nevertheless, these findings support an enhanced effect of the SERoVITALO supplement in women.
An eight-fold increase was observed, equivalent to 682%, in GH levels 120 minutes after a single oral supplement of SER0VITALO. The study had a broad range of ages and BMI's and included both genders. An additional advantage of the present study over previous GH evaluations is that it contained a placebo control group and was randomized and double-blinded.
These findings demonstrate that a specialized low-dose amino acid supplement can significantly increase short-term GH levels. Future studies will examine whether such increases in GH with oral amino acid supplementation increase fat-free mass and strength. This indeed may be the case, since elderly subjects administered oral GH
secretagogues for 6 and 12 months have sustained increases in lean body mass and improved physical function.
The absolute magnitudes of these results are somewhat difficult to directly correlate among past studies, as commercial GH assays use different antibodies to target specific GH epitopes. Therefore, different antibodies and assays are less likely to recognize some specific isoforms and fragments of the GH molecule. This results in variability of the normal range of the GH measurements in different assays.
Indeed, the same GH sample measured using different assays can vary 2-3 fold, limiting the ability to compare actual GH levels across studies. Nevertheless, the mean levels of GH reached after the subcutaneous injection of 0.06 IU of HGH in the treatment of GH
deficient subjects was 0.4ng/ml, a value that was clearly in the range of values seen in our study with oral amino acids.
Findings obtained from a randomized, blinded, placebo-controlled study strengthen the evidence that oral administration of amino acids, when compounded properly, can increase GH serum levels, wherein SERDVITALO administration showed an 8-fold, equivalent to a 682% increase in GH levels 120 minutes after a single oral dose. In addition, we elucidate some mechanistic details for these significant GH
increases as through somatostatin inhibition, supported by our results on the 120 minute results on T3 levels in the same subjects.
An eight-fold increase was observed, equivalent to 682%, in GH levels 120 minutes after a single oral supplement of SER0VITALO. The study had a broad range of ages and BMI's and included both genders. An additional advantage of the present study over previous GH evaluations is that it contained a placebo control group and was randomized and double-blinded.
These findings demonstrate that a specialized low-dose amino acid supplement can significantly increase short-term GH levels. Future studies will examine whether such increases in GH with oral amino acid supplementation increase fat-free mass and strength. This indeed may be the case, since elderly subjects administered oral GH
secretagogues for 6 and 12 months have sustained increases in lean body mass and improved physical function.
The absolute magnitudes of these results are somewhat difficult to directly correlate among past studies, as commercial GH assays use different antibodies to target specific GH epitopes. Therefore, different antibodies and assays are less likely to recognize some specific isoforms and fragments of the GH molecule. This results in variability of the normal range of the GH measurements in different assays.
Indeed, the same GH sample measured using different assays can vary 2-3 fold, limiting the ability to compare actual GH levels across studies. Nevertheless, the mean levels of GH reached after the subcutaneous injection of 0.06 IU of HGH in the treatment of GH
deficient subjects was 0.4ng/ml, a value that was clearly in the range of values seen in our study with oral amino acids.
Findings obtained from a randomized, blinded, placebo-controlled study strengthen the evidence that oral administration of amino acids, when compounded properly, can increase GH serum levels, wherein SERDVITALO administration showed an 8-fold, equivalent to a 682% increase in GH levels 120 minutes after a single oral dose. In addition, we elucidate some mechanistic details for these significant GH
increases as through somatostatin inhibition, supported by our results on the 120 minute results on T3 levels in the same subjects.
-11-Example 3 To test the effect of the nutritional supplement on endurance and fat metabolism, a double-blind clinical study was conducted involving 12 healthy subjects [7 males, 5 females; mean age = 31 6 years; body mass index= 25.7 3.8 ranging from 20.3 to 32.2 kg/m2]. Each subject reported to the Fitness Testing Facility (PEAK, University of Utah College of Health) after an overnight fast. Upon arrival each subjects underwent standard measurements of weight, height, body fat percent (Bod Pod), and resting metabolic rate (RMR, indirect calorimerty). Daily calorie expenditure was estimated based on the additive evaluations of measured RMR, estimated Lifestyle and Activity (defined as the number of calories burned performing daily activities including working, playing eating, etc.), and estimated Exercise (defined as an estimate of the number of calories burned during exercise based on daily activity level).
Following the baseline measurements, subjects then consumed a standard breakfast (Egg McMuffin, 300 Calories; 12g fat; 29g carbohydrates; 18g protein).
Subjects rested for a further 45 min to reach a post-absorptive state, then underwent a Maximal Aerobic Fitness Test of graded exercise, completed on a treadmill. Subjects' oxygen uptake was measured using a metabolic cart, and V02max was quantified.
Subjects were then provided a two week supply of a novel supplement StRoVITALO (2.9g/dose blend of 1-lysine HC1, 1-arginine HCl, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder). The novel SERDVITALO blend has been shown previously to increase serum human growth hormone hGH levels by 8 times (equivalent to 682%) 120 minutes after a single dose in healthy male and female volunteers. In this study, subjects were instructed to consume one dose of the supplement on an empty stomach, two hours after dinner prior to bedtime, every night for the two-week study duration. Following the final dose, each subject returned to the PEAK Fitness Testing Facility, University of Utah College of Health after an overnight fast (without having consumed their last dose of the supplement since the previous night). Upon arrival each subjects underwent the identical test protocols as the baseline test day. The data from the two measurement days were then analyzed. Consistent with our priori hypothesis that the supplement would increase improve endurance parameters with its ability to increase in hGH
Following the baseline measurements, subjects then consumed a standard breakfast (Egg McMuffin, 300 Calories; 12g fat; 29g carbohydrates; 18g protein).
Subjects rested for a further 45 min to reach a post-absorptive state, then underwent a Maximal Aerobic Fitness Test of graded exercise, completed on a treadmill. Subjects' oxygen uptake was measured using a metabolic cart, and V02max was quantified.
Subjects were then provided a two week supply of a novel supplement StRoVITALO (2.9g/dose blend of 1-lysine HC1, 1-arginine HCl, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder). The novel SERDVITALO blend has been shown previously to increase serum human growth hormone hGH levels by 8 times (equivalent to 682%) 120 minutes after a single dose in healthy male and female volunteers. In this study, subjects were instructed to consume one dose of the supplement on an empty stomach, two hours after dinner prior to bedtime, every night for the two-week study duration. Following the final dose, each subject returned to the PEAK Fitness Testing Facility, University of Utah College of Health after an overnight fast (without having consumed their last dose of the supplement since the previous night). Upon arrival each subjects underwent the identical test protocols as the baseline test day. The data from the two measurement days were then analyzed. Consistent with our priori hypothesis that the supplement would increase improve endurance parameters with its ability to increase in hGH
-12-levels, the decision was made to reject the null only if the data supported the one directional alternative consistent with a favorable response to the supplement.
Statistical significance was assumed for P<0.05.
Mean V02max increased by 6% from 44.9 8.1 at baseline to 47.7 9.2mL/kg/min (3.69 0.96 to 3.91 1.02L/min), demonstrating a statistically significant differential effect compared to baseline (P=0.02). After the period of supplementation with SERoViTALO, the mean RMR increased by 2.7% from 1687 330 to 1733 288kcaUday with a statistical trend towards significance compared to baseline (P=0.165). Estimated daily calorie expenditure also increased by 2.7%
from 1687 330 to 1733 288kca1/day with trend towards significance (P=0.166).
After two weeks of supplementation with the supplement SER0VITALO, (taken on an empty stomach, two hours after dinner prior to bedtime, every night), both RMR
and estimated daily calorie expenditure tended to increase, evidencing the potential of the supplement to impart long-term fat burning effects. Additionally, endurance as measured by VO2max in the post-absorptive state significantly improved with a measured 6% increase. Overall, the SERoViTALO supplement was shown to increase parameters of endurance, energy, and vitality.
While embodiments of the present invention have been described herein for purposes of illustration, many modifications and changes will become apparent to those skilled in the art. Accordingly, the appended claims are intended to encompass all such modifications and changes as fall within the true spirit and scope of this invention
Statistical significance was assumed for P<0.05.
Mean V02max increased by 6% from 44.9 8.1 at baseline to 47.7 9.2mL/kg/min (3.69 0.96 to 3.91 1.02L/min), demonstrating a statistically significant differential effect compared to baseline (P=0.02). After the period of supplementation with SERoViTALO, the mean RMR increased by 2.7% from 1687 330 to 1733 288kcaUday with a statistical trend towards significance compared to baseline (P=0.165). Estimated daily calorie expenditure also increased by 2.7%
from 1687 330 to 1733 288kca1/day with trend towards significance (P=0.166).
After two weeks of supplementation with the supplement SER0VITALO, (taken on an empty stomach, two hours after dinner prior to bedtime, every night), both RMR
and estimated daily calorie expenditure tended to increase, evidencing the potential of the supplement to impart long-term fat burning effects. Additionally, endurance as measured by VO2max in the post-absorptive state significantly improved with a measured 6% increase. Overall, the SERoViTALO supplement was shown to increase parameters of endurance, energy, and vitality.
While embodiments of the present invention have been described herein for purposes of illustration, many modifications and changes will become apparent to those skilled in the art. Accordingly, the appended claims are intended to encompass all such modifications and changes as fall within the true spirit and scope of this invention
Claims (19)
1. Use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising:
0.1 to 6 mmol L-arginine;
0.1 to 8 mmol Oxo-proline;
0.1 to 12 mmol L-lysine;
0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
0.1 to 6 mmol L-arginine;
0.1 to 8 mmol Oxo-proline;
0.1 to 12 mmol L-lysine;
0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
2. The use according to claim 1, wherein the nutritional supplement is for administration from one to three times daily.
3. The use according to claim 1 or 2, wherein the nutritional supplement is for administration once a week.
4. The use according to any one of claims 1 to 3, wherein the nutritional supplement is for administration on an empty stomach.
5. The use according to any one of claims 1 to 4, wherein the human being is a healthy female human.
6. The use according to any one of claims 1 to 4, wherein the human being is a healthy male human that is at least 30 years of age.
7. Use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising:
3.44 mmol L-arginine;
5.30 mmol Oxo-proline;
8.21 mmol L-lysine;
Date Recue/Date Received 2020-11-10 6.13 prnol N-acetyl L-cysteine; and 6.84 umol L-glutamine.
3.44 mmol L-arginine;
5.30 mmol Oxo-proline;
8.21 mmol L-lysine;
Date Recue/Date Received 2020-11-10 6.13 prnol N-acetyl L-cysteine; and 6.84 umol L-glutamine.
8. The use according to claim 7, wherein the nutritional supplement is to be used in an amount of 2.9 grams.
9. The use according to claim 7 or 8, wherein the nutritional supplement is in powder, tablet, capsule, liquid, or wafer form.
10. The use according to any one of claims 7 to 9, wherein the nutritional supplement is for administration from one to three times daily.
11. The use according to any one of claims 7 to 10, wherein the nutritional supplement is for administration once a week.
12. The use according to any one of claims 7 to 11, wherein the nutritional supplement is for administration on an empty stomach.
13. The use according to any one of claims 7 to 12, wherein the human being is at least 30 years old.
14. A nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising:
0.1 to 6 mmol L-arginine;
0.1 to 8 mmol Oxo-proline;
0.1 to 12 mmol L-lysine;
0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
Date Recue/Date Received 2020-11-10
0.1 to 6 mmol L-arginine;
0.1 to 8 mmol Oxo-proline;
0.1 to 12 mmol L-lysine;
0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
Date Recue/Date Received 2020-11-10
15. A nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising:
3.44 mmol L-arginine;
5.30 mmol Oxo-proline;
8.21 mmol L-lysine;
6.13 Ilmol N-acetyl L-cysteine; and 6.84 Ilmol L-glutamine.
3.44 mmol L-arginine;
5.30 mmol Oxo-proline;
8.21 mmol L-lysine;
6.13 Ilmol N-acetyl L-cysteine; and 6.84 Ilmol L-glutamine.
16. The use according to any one of claims 1 to 6, wherein the nutritional supplement further comprises schizonepeta.
17. The use according to any one of claims 7 to 13, wherein the nutritional supplement further comprises schizonepeta.
18. The nutritional supplement according to claim 14, which further comprises schizonepeta.
19. The nutritional supplement according to claim 15, which further comprises schizonepeta.
Date Recue/Date Received 2020-11-10
Date Recue/Date Received 2020-11-10
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/623,114 US8734864B2 (en) | 2012-09-20 | 2012-09-20 | Methods for increasing human growth hormone levels |
US13/623,118 | 2012-09-20 | ||
US13/623,117 | 2012-09-20 | ||
US13/623,112 US8722114B2 (en) | 2012-09-20 | 2012-09-20 | Compositions and methods for increasing human growth hormone levels |
US13/623,112 | 2012-09-20 | ||
US13/623,118 US9066953B2 (en) | 2012-09-20 | 2012-09-20 | Methods for increasing endurance and fat metabolism in humans |
US13/623,117 US8715752B2 (en) | 2012-09-20 | 2012-09-20 | Compositions for increasing human growth hormone levels |
US13/623,114 | 2012-09-20 | ||
PCT/US2013/060669 WO2014047321A1 (en) | 2012-09-20 | 2013-09-19 | Compositions and methods for increasing human growth hormone levels |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2885566A1 CA2885566A1 (en) | 2014-03-27 |
CA2885566C true CA2885566C (en) | 2021-08-10 |
Family
ID=50341939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2885566A Active CA2885566C (en) | 2012-09-20 | 2013-09-19 | Compositions and methods for increasing human growth hormone levels |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2885566C (en) |
WO (1) | WO2014047321A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000000757A (en) * | 1998-06-03 | 2000-01-15 | 배오성 | Composition of herb medicine for promting release of growth hormone and promoting agent for release of growth hormone using the same |
US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
-
2013
- 2013-09-19 WO PCT/US2013/060669 patent/WO2014047321A1/en active Application Filing
- 2013-09-19 CA CA2885566A patent/CA2885566C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2885566A1 (en) | 2014-03-27 |
WO2014047321A1 (en) | 2014-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9066953B2 (en) | Methods for increasing endurance and fat metabolism in humans | |
US9238023B2 (en) | Methods for improving health in humans | |
US8808764B2 (en) | Methods and compositions for increasing growth hormones | |
US8734864B2 (en) | Methods for increasing human growth hormone levels | |
US8722114B2 (en) | Compositions and methods for increasing human growth hormone levels | |
US10292964B2 (en) | Compositions for increasing human growth hormone levels | |
US9339490B2 (en) | Methods and compositions for increasing sex steroids and growth hormones | |
CA2885560C (en) | Methods for improving thyroid function in healthy humans | |
US8765195B2 (en) | Methods and compositions for increasing sex steroids and growth hormones | |
CA2885566C (en) | Compositions and methods for increasing human growth hormone levels | |
US10300101B2 (en) | Methods and compositions for enhancing or maintaining fertility | |
US10292957B2 (en) | Compositions and methods for treating fibromyalgia | |
US10894072B2 (en) | Compositions and methods for treating fibromyalgia | |
CA2840809C (en) | Methods and compositions for increasing growth hormones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20180914 |